A mathematical model of CD19- relapses after CAR-T cell treatment in B cell leukemia

  1. Salvador Chulián 12
  2. Ana Niño-López 12
  3. Álvaro Martínez Rubio 12
  4. María Rosa 12
  1. 1 Department of Mathematics, Universidad de Cádiz, Puerto Real, Cádiz, Spain
  2. 2 Biomedical Research and Innovation Institute of Cadiz (INiBICA). Hospital Universitario Puerta del Mar, Cádiz, Spain
Actas:
International Conference on Mathematical Analysis and Applications in Science and Engineering (ICMASSC22)

Editorial: Universidade Porto

ISBN: 978-989-53496-3-0

Año de publicación: 2022

Páginas: 43-45

Tipo: Aportación congreso

GOOGLE SCHOLAR

Resumen

B cell Acute Lymphoblastic Leukaemia (B-ALL) is the most common type of pediatric leukemia. Modern therapies have improved survival rates, but approximately 15-20 % of patients relapse. For such patients, a treatment possibility is chimeric antigenic receptor (CAR) T cells as it presents high rates of response. CAR T cells are able to recognize target cells with the antigen CD19, which is expressed in B-ALL. Here, we construct a mathematical model based on partial diferential equations, where we simulate di↵erent scenarios regarding this therapy. We focus on how CAR-T cells therapy can lead to CD19 relapses, where leukemic cells loss the antigen and thus continue growing. We propose this model which could readily extend to other haematological malignancies considering this kind of immunotherapy